top of page
News
CellVax is featured in the newspaper "Folha de São Paulo", Brazil.
Fernando Kreutz, CEO of CellVax, details how the vaccine developed, already being tested in the United States, improves the treatment of...
CellVax Therapeutics
18 de fev.
Fernando Kreutz in an interview with Jornal Da Gazeta, in Brazil
Click on the video to watch it on YouTube. To insert English subtitles, use the player menu.
CellVax Therapeutics
18 de fev.
We discovered a new way to modify this cell
In the future, the technology could be adapted to other types of disease.
CellVax Therapeutics
18 de fev.
Prostate cancer vaccine developed in Brazil could revolutionize the treatment of the disease.
Prostate cancer vaccine developed in Brazil could revolutionize the treatment of the diseas
CellVax Therapeutics
18 de fev.
CellVax is a featured subject on the "Fala Brasil" program on the Brazilian TV channel Record News.
The therapy was tested in Brazil and is being tested in the United States. The method uses modified tumor cells to activate the patient's im
CellVax Therapeutics
18 de fev.
Brazilian vaccine against prostate cancer begins to be tested in the USA
The CellVax vaccine promises individualized treatments. After 25 years of studies in Brazil, it received the green light from the FDA,...
CellVax Therapeutics
18 de fev.
TV Record News interviews Fernando Kreutz
Treatment developed by CellVax is featured in the Brazilian press and Fernando Kreutz, CEO, is interviewed by a Brazilian TV channel.
CellVax Therapeutics
17 de fev.
If the results from 230 American patients are validated, the immunotherapy could be approved in about 18 months.
Brazilian-Developed Cancer Vaccine Enters Testing Phase in the U.S.
CellVax Therapeutics
30 de jan.
CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy
CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy
CellVax Therapeutics
31 de out. de 2024
CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent
CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent
CellVax Therapeutics
31 de out. de 2024
Theragent to act as partner for CellVax’s Phase II cancer therapy
Theragent to act as partner for CellVax’s Phase II cancer therapy
CellVax Therapeutics
31 de out. de 2024
Developing the next generation of personalized immunotherapy
1951 NW 7TH Ave
3rd Floor | Suite 130
Miami | FL | 33136
© 2025 CellVax Therapeutics
bottom of page